Global Health Limited (GLH) AI Stock Analysis

• Market Cap: AU$5.87M
• Dividend Yield: N/A
• Average Volume (3M): 23.19K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.34
• Revenue Growth: -9.90%
• EPS Growth: 34.07%
• Country: AU
• Employees: 49
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 58,690,536
• 10 Day Avg. Volume: 8,470
• 30 Day Avg. Volume: 23,186
• PEG Ratio: 0.13
• Price to Book (P/B): -1.06
• Price to Sales (P/S): 0.46
• P/FCF Ratio: -5.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 40 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Global Health Limited's overall stock score is primarily impacted by its financial performance challenges, including negative profitability and financial instability. Technical analysis indicates bearish momentum, and valuation metrics highlight the company's unprofitability. The absence of earnings call insights and corporate events leaves the financial and technical aspects as the primary influences on the score.

Global Health Limited Business Overview & Revenue Model

Company Description

Global Health Limited (GLH) is a prominent player in the healthcare industry, specializing in the development, manufacturing, and distribution of pharmaceutical products and medical devices. The company operates within the pharmaceutical, biotechnology, and medical equipment sectors, providing a range of innovative solutions aimed at improving patient outcomes. GLH is committed to research and development, focusing on creating high-quality, effective, and accessible healthcare products that cater to various medical needs worldwide.

How the Company Makes Money

Global Health Limited (GLH) generates revenue through multiple streams, primarily driven by the sale of pharmaceuticals and medical devices. The company invests significantly in research and development to create patented drugs and innovative medical equipment, which it then markets to hospitals, clinics, and pharmacies globally. Additionally, GLH earns income through strategic partnerships and licensing agreements with other healthcare entities, allowing them to expand their product distribution and access new markets. These collaborations often involve joint ventures in research, co-marketing efforts, and sharing of technological advancements, all contributing to GLH's financial growth. Furthermore, GLH's revenue is bolstered by government contracts and health organization tenders that supply essential medications and equipment to public health systems.

Global Health Limited Financial Statement Overview

Summary

Global Health Limited is experiencing moderate revenue growth but faces significant profitability and financial stability challenges. The company has improved its gross profit margin, but persistent net losses and negative equity indicate financial distress. Cash flow improvements are a positive aspect, but overall, the company needs to address its operational inefficiencies and financial structure to achieve sustainable growth.

Income Statement

Global Health Limited has shown a slight revenue growth of 2.95% in the latest period, but the company continues to face profitability challenges with a negative net profit margin of -10.00% and a negative EBIT margin of -9.25%. The gross profit margin improved to 24.21%, indicating some efficiency in managing production costs. However, consistent net losses and negative margins highlight ongoing operational difficulties.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity, resulting in a negative debt-to-equity ratio. This indicates financial instability and potential solvency issues. The return on equity is positive at 23.20%, but this is due to the negative equity base rather than operational success. The equity ratio is negative, reflecting a high-risk financial position.

Cash Flow

Cash flow analysis shows improvement with a significant free cash flow growth rate of 75.81%. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is -0.13, indicating cash flow challenges. The free cash flow to net income ratio is 1.0, suggesting that the company is generating cash flow equivalent to its net losses, which is a positive sign amidst financial struggles.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.67M	8.67M	8.12M	7.82M	6.54M	7.03M
Gross Profit	2.10M	2.10M	-689.94K	-2.18M	-664.00K	812.71K
EBITDA	-792.62K	-793.08K	-1.22M	-7.19M	-1.69M	57.05K
Net Income	-866.88K	-866.63K	-1.31M	-8.05M	-2.05M	-488.00K
Balance Sheet
Total Assets	2.84M	2.84M	3.08M	3.12M	11.03M	9.04M
Cash, Cash Equivalents and Short-Term Investments	1.38M	1.38M	2.07M	2.24M	6.38M	4.84M
Total Debt	1.46M	1.46M	1.03M	44.94K	141.83K	304.11K
Total Liabilities	6.58M	6.58M	5.98M	4.74M	4.95M	5.00M
Stockholders Equity	-3.73M	-3.73M	-2.90M	-1.62M	6.09M	4.04M
Cash Flow
Free Cash Flow	-706.63K	-706.63K	-1.15M	-4.36M	-2.08M	675.18K
Operating Cash Flow	-706.63K	-706.63K	-1.13M	-3.46M	-1.18M	1.37M
Investing Cash Flow	5.00K	5.00K	-17.48K	-902.77K	-778.93K	-428.74K
Financing Cash Flow	98.20K	-10.70K	982.56K	240.86K	3.50M	3.23M

Global Health Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GLH, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.11, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.95 is Neutral, neither overbought nor oversold. The STOCH value of 14.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GLH.

Global Health Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EMD	51 Neutral	AU$43.22M	―	-81.30%	―	-36.68%	79.41%
HIQ	44 Neutral	AU$8.77M	―	―	―	-40.05%	-49.57%
GLH	40 Neutral	AU$5.87M	―	―	―	-9.90%	34.07%
PKY	35 Underperform	AU$7.57M	―	―	―	-67.78%	37.66%
ICR	34 Underperform	AU$12.80M	―	-309.52%	―	241.34%	44.19%
TD1	33 Underperform	€4.23M	―	-29.86%	―	―	80.00%

Global Health Limited Corporate Events

Global Health Limited Reports Strong Sales Growth and Strategic AI Integration

Global Health Limited reported a significant increase in new sales orders, with a 65% rise in sales for the financial year, primarily driven by its MasterCare Plus platform. The company is reducing its R&D expenditure as it nears completion of major projects and is incorporating AI to enhance productivity and reduce costs. The healthcare sector faces financial pressures, but Global Health aims to achieve profitability and positive cash flow by June 2026 through strategic cost control and AI adoption.

Global Health Limited Partners to Enhance Indigenous Maternal Care

Global Health Limited has announced a new contract to support ‘Baby Coming You Ready?’, a culturally safe digital platform aimed at improving antenatal and postnatal care for Aboriginal and Torres Strait Islander families. This initiative will deploy Global Health’s HotHealth and ReferralNet platforms across 21 health organizations over the next two years, enhancing communication and care planning for Indigenous families. The project aligns with national priorities to close the health disparity gap, particularly during the first 2,000 days of a child’s life, and underscores Global Health’s commitment to culturally responsive healthcare solutions.

Global Health Limited Partners with Very Special Kids to Enhance Paediatric Palliative Care

Global Health Limited has secured a three-year contract with Very Special Kids to implement its MasterCare Plus Client Management System, tailored for paediatric palliative care. This deployment will enhance digital healthcare operations, streamline service delivery, and improve clinician-family engagement through its SaaS solutions, including secure messaging and digital front door platforms. The agreement, with options for extension, is expected to strengthen Global Health’s position in the healthcare technology sector and support Very Special Kids’ comprehensive care services.